Objectives: Epigenetic modifiers were important players in the development of haematological malignancies and sensitivity to therapy. Mutations of SET domain-containing 2 (SETD2), a methyltransferase that catalyses the trimethylation of histone 3 on lysine 36 (H3K36me3), were found in various myeloid malignancies. However, the detailed mechanisms through which SETD2 confers chronic myeloid leukaemia progression and resistance to therapy targeting on BCR-ABL remain unclear. 
| INTRODUC TI ON
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder caused by the malignant transformation of hematopoietic stem cells (HSCs) through BCR-ABL oncogene initiation. 1 Resulting from a t(9,22) (q34;q11) chromosome translocation, the oncogene encodes a chimeric oncoprotein with constitutive tyrosine kinase activity. [2] [3] [4] Imatinib, a classical tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL oncogene, has been a front-line drug for the clinical treatment of CML, leading to cytogenetic and molecular remission of the disease. [5] [6] [7] [8] [9] However, approximately 90% of treated patients ultimately develop imatinib resistance, resulting in disease relapse and poor outcomes. [10] [11] [12] Approximately 50% of the CML cases with imatinib resistance have been proven to be caused by BCR-ABL kinase domain mutations (including T315I, Q252H, G250E, E255K/V and Y253H) as well as locus amplification, 10, 13, 14 which can be relatively well cured by second-generation (Dasatinib, Nilotinib, and Bosutinib) and third-generation (Ponatinib) TKIs. [15] [16] [17] Additionally, the primary resistance driven by leukaemic stem cells (LSCs) has turned out to be a troublesome challenge, demanding prompt solutions. [18] [19] [20] [21] With their traits of self-renewal, quiescence and reduced differentiation, 19, 20 
the LSCs derived from the BCR-ABL-initiated malignant transformation of
HSCs show BCR-ABL -independent behaviour, 10,22 a fact that is exemplified by the failure of single TKI treatments to eliminate these cells. 23 Therefore, the exploration of potential targets of LSCs and the generation of novel therapeutic approaches for their specific eradication would significantly benefit the outcomes of patients with CML.
Epigenetic modifiers are involved in various myeloid malignancies and in normal hematopoiesis. For example, DNA methyltransferase 1 (DNMT1), DNMT3A and DNMT3B play key roles in uniquely regulating the differentiation of hematopoietic stem cells and progenitor cells. [24] [25] [26] [27] [28] Meanwhile, genetic alterations through DNA methylation (DNMT3A, TET2 and IDH1/2) and histone modifications (EZH2, ASXL1, KMT2A, CREBBP and HDAC2/3) are found in all types of myeloid haematological disorders. 29, 30 Histone deacetylations have been recently supposed to exert a pivotal role in leukemogenesis, as exemplified by the emergence of histone deacetylase inhibitors as therapeutic measures for targeting LSCs. 20, 31 SET domain-containing 2 (SETD2) is the major mammalian methyltransferase responsible for catalysing the trimethylation of histone 3 on lysine 36 (H3K36me3). 32 Mutations of SETD2 have been found in various types of tumours, such as clear cell renal cell carcinoma, 33, 34 breast cancer, 35, 36 glioma, 37 acute leukaemia and chronic lymphocytic leukaemia. 38, 39 In the recent decades, research studies on the loss-of-function mutations of SETD2 have been carried out to investigate the initiation and propagation of acute leukaemia by equipping LSCs with increased self-renewal potential. 38, 40 Specifically, the downregulation of SETD2 was shown to contribute to chemotherapeutic resistance in MLL-AF9 fusion protein-associated leukaemia. 41 In mouse models with SETD2 specifically depleted, the loss of the methyltransferase disrupted normal hematopoiesis through the impairment of hematopoietic stem cell differentiation, thereby further facilitating their malignant transformation. 42, 43 Herein, we demonstrate that the downregulation of SETD2 facilitates imatinib resistance in CML cells, with LSC marker upregulation, which could be successfully rescued by SETD2 overexpression.
Additionally, by restoring the H3K36me3 level through treatment with JIB-04 (a small-molecule inhibitor of H3K36me3 demethylase 41 ), the sensitivity of CML cells towards imatinib was effectively increased, providing a potential therapeutic strategy to overcome imatinib-resistant CML.
| MATERIAL S AND ME THODS

| Cell culture and drug treatment
The TF1-BA, TF1-BAR, KCL- in a humidified 5% CO 2 atmosphere for 2.5-3 hours. Finally, the absorbance at 450 nm was measured using a microplate reader. 
| Cell proliferation assay
| Apoptosis assay
| Cell cycle analysis
Cells were cultured with the experimental drugs in 6-well plates (1 × 10 6 cells/well) at 37°C for 72 hours and then labelled with 10 µmol/L 5-ethynyl-2-deoxyuridine (EdU) for 3 hours.
Subsequently, the cells were harvested for EdU staining, using the Click-iT EdU Flow Cytometry Assay Kit (Cat#C1024; Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and finally analysed by flow cytometry.
| Quantitative RT-PCR
Total RNA was isolated from the cells using the TRIzol reagent (Invitrogen) and then reverse-transcribed to cDNA using the PrimeScript RT Reagent Kit (Takara, Tokyo, Japan) according to the manufacturer's instructions. qRT-PCR was performed using the SYBR Premix ExTaq (Takara) and an Applied Biosystems 7500 Fast
Real-Time PCR system. The relative expression of the mRNA was analysed using the 2 −ΔΔC t method and normalized to the expression of β-actin. All experiments were repeated three times. The PCR primer sequences used in this study are shown in Supporting Information Table S3 . 
| Western blot assay
| Colony formation assay
Cells were maintained in methylcellulose medium (Cat#H4434; STEMCELL Technologies, Vancouver, BC, Canada) supplemented with 20 ng/mL human interleukin-6 (Cat#200-06-20UG; PeproTech, Rocky Hill, NJ) and 20 ng/mL human granulocyte/colony-stimulating factor (Cat#300-23-10UG; PeproTech), in 35-mm dishes with incubation at 37°C under 5% CO 2 and 95% humidity. After 10-12 days, colonies were observed and counted with an inverted microscope.
| mRNA sequencing analysis
Total RNA was extracted from the TF1-BA and TF1-BAR cells After discarding adaptor sequences with poor quality, clean reads were collected and analysed using the TopHat-CufflinksCuffmerge-Cuffdiff pipeline with default parameters. The reads were mapped to the Homo sapiens GRCh38 reference genome using TopHat v2.0.13. We used DESeq2 for differential gene expression analysis, with the differentially expressed genes defining as |log 2 Foldchange| ≥ 1 and q value <0.05. Fold change is the ratio of the two groups after homogenization. The q value (padj value, the corrected P value) is calculated with R package (DESeq2) and adjusted by Benjamini-Hochberg method according to the P value.
This experiment was conducted by Annoroad Gene Tech. (Beijing)
Co., Ltd. The RNA-seq dataset was submitted into the GEO database, and the accession number is GSE124894.
| ChIP-quantitative PCR
To crosslink proteins to DNA, cells were incubated with 1% formaldehyde at room temperature for 10 minutes and then subjected to micrococcal nuclease treatment to digest the DNA followed by sonication to break the nuclear membrane. Finally, chromatin fragments in the range of 150-900 bp were obtained. After analysis of the digestion and concentration, the crosslinked chromatin Table S4 .
| Statistical analysis
Data with two groups were analysed using the unpaired Student's t test, and data with three or more groups were analysed by ANOVA.
GraphPad Prism 7 software was used for all graphical and statistical analyses, with a P-value <0.05 (*), <0.01 (**) or <0.001 (***) considered statistically significant. Experimental results are expressed as the mean ± standard deviation.
| RE SULTS
| SETD2 downregulation in imatinib-resistant cells is restored by protease inhibitor treatment
Imatinib-sensitive (TF1-BA) 44 and imatinib-resistant (TF1-BAR) cell models were created by Dr Voetzel in the laboratory of Dr
Veronique Maguer-Satta, as outlined in Figure 1A . To uncover the role of SETD2 in imatinib resistance development in CML, we first was unchanged ( Figure 1D ). Additionally, the downregulation of both SETD2 and H3K36me3 in the TF1-BAR cells could be successfully restored by protease inhibitor (MG132) treatment ( Figure 1E ).
These data indicated that the SETD2 deficiency was associated with imatinib resistance.
| SETD2 facilitates imatinib sensitivity in CML cell lines
To further investigate the role of SETD2 in the process of imatinib resistance acquisition by CML cells, we next used SETD2-targeted Figure S2 ). 
| SETD2 deficiency upregulates the
| SETD2 deficiency upregulates a subset of genes involved in stemness regulation
To Figure S3 ). These studies illustrated that therapies that target H3K36me3 deficiency might be of great value in the treatment of imatinib resistance due to SETD2 loss. 
| D ISCUSS I ON
In our study, we discovered that SETD2 deficiency significantly promoted both imatinib resistance and LSC marker upregulation in CML cells. JIB-04 could efficiently improve the sensitivity of CML cells to imatinib by inhibiting the biological process of histone demethylation, indicating it as a promising therapeutic agent for imatinib-resistant CML.
SETD2, an important histone modifier responsible for producing
H3K36me3, 32 participates in many of the biological processes for maintaining mitosis and genomic stability, namely identification of the splicing machinery and selection of splicing sites 53 ; elongation of RNA polymerase and prevention of spurious transcriptional initiation 54 ; recognition of DNA repair protein and activation of mismatch repair and homologous recombination 55, 56 ; and remoulding of chromatin and the cytoskeleton through tubulin methylation. 57, 58 Although the genetic disruptions of SETD2 have been validated in various haematological malignancies, including acute myeloid leukaemia, acute lymphocytic leukaemia and chronic lymphocytic leukaemia, 38, 39 whether these genetic changes are involved in CML had remained unsolved. Our finding that the SETD2 deficiency occurs at the post-translational level, with unchanged mRNA expression, during imatinib resistance in CML provides evidence that in addition to genetic changes, the post-translational mechanisms also play a vital role in promoting the progression of leukaemia triggered by SETD2 dysregulation. However, whether SETD2 is mutated in patients with CML, especially those who harboured IM resistance, needs to be further studied.
The repression, but not total loss, of SETD2 facilitated the imatinib resistance of CML, which is consistent with the finding Data are presented as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.00, by ANOVA that the heterozygous depletion of SETD2 accelerated MLL-AF9 leukaemia propagation, whereas its homozygous depletion greatly dampened the latency. 41 Another interesting fact is that the homozygous depletion of SETD2 is detrimental to hematopoietic stem cells, 42, 43 and thus, we speculate that the moderate expression of SETD2 is required for maintenance of the stemness in LSCs that is mediated by the upregulation of oncogenic transcription factors such as MYCN and ERG, both of which accelerate the development of acute leukaemia and lead to poor patient outcomes. Taken together, the results of our study have built an oncogenic role for SETD2 downregulation in CML with imatinib resistance.
Nonetheless, because we only measured these biological effects using in vitro experiments, further in vivo verification of these effects is needed as well as validation in clinical samples. Importantly, however, this is the first report to suggest that targeting H3K36me3 deficiency through the use of JIB-04 could be a novel strategy to improve clinical treatments for imatinib resistance. Our study paves the way for utilizing SETD2 to identify potential diagnostic strategies or drug targets to eventually cure CML, especially in patients with imatinib resistance.
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